Beovu (brolucizumab-dbll) / Novartis - LARVOL DELTA

Novel Resolution of Multilayered Pigment Epithelial Detachment Lamellae Following Brolucizumab Treatment-A Case Report. (PubMed, Case Rep Ophthalmol Med) - "Observations: An 80-year-old gentleman with polypoidal choroidal vasculopathy developed MLPED from long-term ranibizumab treatment. Brolucizumab's mechanism of action, including its potent antivascular endothelial growth factor properties and enhanced tissue penetration, may contribute to the collapse of MLPED by modulating subretinal pigment epithelial fluid dynamics. Further research into molecular pathways, cellular interactions, and safety profiles is warranted to optimize the therapeutic role of brolucizumab."

Journal • Age-related Macular Degeneration

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration. (PubMed, Ophthalmol Ther) - "Treatment with brolucizumab is effective in patients previously treated with other therapeutic molecules. The best outcomes were achieved in patients who switched therapy to brolucizumab early in their disease. Treatment with brolucizumab in this population demonstrated an acceptable risk profile, with only one intraocular inflammatory event out of 302 intravitreal injections."

Journal • Real-world evidence • Age-related Macular Degeneration • Hematological Disorders • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India. (PubMed, Indian J Ophthalmol) - "Brolucizumab 6 mg IVI, given as per the prescribing information, demonstrated a positive benefit/risk profile in Indian patients with nAMD, with no new safety signals."

Journal • P4 data • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis. (PubMed, Acta Ophthalmol) - "The reference for comparison was monthly ranibizumab...For CRT, small but statistically significant improvements over the reference were observed for brolucizumab 3 mg (-27.9 μm) or 6 mg (-38.1 μm) in loading dose (LD) then every 8-12 weeks, aflibercept 8 mg in LD then every 12 (-26.9 μm) or 16 weeks (-32.1 μm), faricimab 6 mg in LD then treat-and-extend (-18.1 μm) and aflibercept 2 mg in LD then every 8 weeks (-11.3 μm)...When results are considered simultaneously, faricimab 6.0 mg or aflibercept 8.0 mg in a treatment regimen with an LD followed by either a treat-and-extend regimen or a fixed 12- or 16-week regimen appears to provide the optimal balance between visual outcomes, anatomical outcomes and the lowest treatment burden. However, studies of the long-term efficacy of newer anti-VEGF drugs are warranted."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Three-year visual outcomes after brolucizumab in patients with neovascular age-related macular degeneration. (PubMed, BMC Ophthalmol) - "The TAE regimen achieved better visual outcomes at 3 years. Residual SRF should be tolerated during the maintenance phase if the change of CFT was little compared to the previous image."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Molecular Dynamic Stability Study of VEGF Inhibitor in Patients with Bladder Cancer. (PubMed, Acta Inform Med) - "Brolucizumab demonstrated strong and competitive binding to VEGFA, with greater affinity than VEGFR2. Brolucizumab exhibits inhibitory and blocking activity against VEGFR2, suggesting its potential as a therapeutic agent in bladder cancer."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection. (PubMed, Korean J Ophthalmol) - "This study elucidates the real-world incidence of brolucizumab associated IOIs, with a description of information related to reinjections after the IOI episodes. A comprehensive understanding of brolucizumab reinjection is essential for its optimal utilization."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases. (PubMed, Int Med Case Rep J) - "This may be due to the fact that aflibercept (8 mg) is a fusion protein rather than an antibody, has lower clearance than a small molecule like brolucizumab, and has a higher anti-VEGF molar concentration than faricimab. It is suggested that aflibercept (8 mg) may be effective for DME in vitrectomized eyes and may merit preferential administration in such cases."

Journal • Diabetic Macular Edema • Hematological Disorders • Ophthalmology • Retinal Disorders

Switch to faricimab in various retinal diseases: real-world data (ARVO 2025) - "Previous treatments included bevacizumab, ranibizumab, aflibercept 2mg, brolucizumab, triamcinolone, and Ozurdex. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 10-year Results of the RENO Study (ARVO 2025) - "The T&E regimen has been effective in maintaining visual acuity in nAMD patients treated with ranibizumab, aflibercept, bevacizumab, brolucizumab, or faricimab for up to ten years of treatment. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane - BRICS Report #1. (PubMed, Semin Ophthalmol) - "Secondary outcome measures will include the best-corrected visual acuity, microperimetry and NEI-VFQ 25 subjective questionnaire. The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM."

Journal • Retinal Disorders

Effects of Socioeconomic Factors on Management and Visual Outcome in Wet Age-Related Macular Degeneration Patients (ARVO 2025) - "Methods This retrospective study analyzed data from 579 patients with neovascular age-related macular degeneration (nAMD) who were treated with aflibercept, bevacizumab, ranibizumab, brolucizumab, and/or faricimab at Bascom Palmer Eye Institute between 2016 and 2024. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Systematic Review and Meta-Analysis: Treatment Patterns and Clinical Outcomes for Diabetic Macular Edema (ARVO 2025) - "Methods A meta-analysis of randomized control trials and retrospective studies was conducted via a search of PubMed, EMBASE, and Web of Science for "diabetic macular edema" AND "visual acuity" AND one of the following therapies: triamcinolone, dexamethasone, fluocinolone acetonide, focal laser, ranibizumab (RBZ), bevacizumab (BVZ), aflibercept (AFL), faricimab, or brolucizumab using PRISMA guidelines.Studies that were 3-24 months in duration and included data on BCVA, CRT, and/or treatment frequency were included. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical data • Retrospective data • Review • Diabetic Macular Edema • Ophthalmology

Preliminary Results of Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients with Persistent Diabetic Macular Edema (BEST, NCT06498050) in China (ARVO 2025) - P4 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Diabetic Macular Edema • Ophthalmology

Efficacy and Safety of Brolucizumab in Proliferative Diabetic Retinopathy: 2-Year Results from the CONDOR Study (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Uncovering Drug-Associated Uveitis Through a National Analysis (ARVO 2025) - "Frequently reported drugs included brolucizumab, nivolumab, and dabrafenib, amongst many others...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ocular Inflammation • Ophthalmology • Uveitis

Real World Outcomes of Faricimab for wet Age-Related Macular Degeneration: High quality data from an Australian Registry (ARVO 2025) - "registry receiving brolucizumab, 0.2% of eyes on faricimab, 0.07% of eyes on bevacizumab, 0.04% of eyes on aflibercept and 0.03% of eyes receiving ranibizumab. It also seems to be associated with inflammation which all these 'VEGF inhibitors' are, we do not know if it is more yet. We need more data to confirm these findings"

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Clinical Outcomes of Refractory Neovascular Aged-related Macular Degeneration after Recovery from Brolucizumab-related Intraocular Inflammation (ARVO 2025) - "Previous anti-VEGFs were aflibercept (n=6, 54.5%), ranibizumab (n=3, 27.3%), and combination of bevacizumab and aflibercept (n=2, 18.2%). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Clinical data • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Demographics and intraocular pressure (IOP) spike rates of neovascular age-related macular degeneration patients: IOP outcomes after 72,855 intravitreal injections from 2014 - 2024 from a single hospital in the United Kingdom (ARVO 2025) - "Included for analysis were Eylea 2mg (Aflibercept), Vabysmo (Faricimab), Ongavia (Ranibizumab biosimilar), Beovu (Brolucizumab), Lucentis (Ranibizumab), and Avastin (Bevacizumab). Our study found that Eylea 2mg, a commonly used anti-VEGF agent, may be associated with increased IOP spike rate compared to other agents. Understanding differences in post-injection IOP profile among various intravitreal agents across broad patient demographics can help ophthalmologists provide well-tailored treatments for wet AMD patients."

Clinical • Age-related Macular Degeneration • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-World Analysis of Anatomical and Functional Outcomes in Eyes with Neovascular Age-related Macular Degeneration Switched from Brolucizumab to Faricimab: A TRUCKEE Study Analysis (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series. (PubMed, Medicina (Kaunas)) - "Vision worsened in one patient who developed IOI after initial IVBr, so IVBr was discontinued and the patient was switched to intravitreal aflibercept with sub-tenon injection of triamcinolone acetonide...In two patients with IOI, not only flares but also IL-8, IP-10, and Flt-3L decreased from 1 to 2 months after IVBr despite continued IVBr. This case series might lead to a better understanding of the pathogenesis of IOI after IVBr."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CCL2 • CX3CL1 • CXCL8 • FLT3 • FLT3LG • IL6

Investigation of functional properties of anti-drug-antibodies to brolucizumab in vascular endothelial cell culture models (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Preclinical • Ocular Inflammation • Ophthalmology

Brolucizumab and Platelet Activation and Reactivity. (PubMed, Curr Eye Res) - "Two different methods were used to examine the interaction of brolucizumab with platelets: 1) A cross-pretreatment experiment was performed with FITC-labeled brolucizumab and bevacizumab; 2) Resting and activated platelets were pretreated with brolucizumab or its solvent or PBS, followed by anti-brolucizumab antibody generated by rabbit immunization. No platelet interaction was observed after increasing brolucizumab concentrations or anti-brolucizumab antibodies in resting and activated platelets. However, brolucizumab might be taken up in platelets."

Journal • Ocular Inflammation • Retinal Vein Occlusion • Vasculitis • SELP

Comparison Between Intravitreal Anti-Vascular Endothelial Growth Factor Monotherapy and Vitrectomy in Age-Related Macular Degeneration with Large Submacular Hemorrhages. (PubMed, J Clin Med) - "Patients undergoing anti-VEGF monotherapy received three monthly loading doses of intravitreal injections of aflibercept or brolucizumab followed by as-needed injections or proactive treatment (anti-VEGF group); those undergoing vitrectomies underwent a 25-gauge vitrectomy and a submacular injection of tissue plasminogen activator (25 μg) and 0.4 mL of air with a microneedle having an outer diameter of 50 μm... Anti-VEGF monotherapy and vitrectomy maintained functionality in patients with large SMHs due to nAMD. Greater CFT was associated with worse 12-month BCVA and less BCVA improvement despite the treatment modality."

Journal • Monotherapy • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan. (PubMed, J Med Econ) - "Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.ConclusionsWhen societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes."

HEOR • Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration